Cargando…
Artificial intelligence in drug discovery and development
• Artificial Intelligence (AI) has revolutionized many aspects of the pharmaceuticals. • AI assistance to pharma industries helps to improve overall life cycle of product. • AI can be implemented in pharma ranging from drug discovery to product management. • Future challenges related to AI and their...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/ https://www.ncbi.nlm.nih.gov/pubmed/33099022 http://dx.doi.org/10.1016/j.drudis.2020.10.010 |
_version_ | 1783598168666013696 |
---|---|
author | Paul, Debleena Sanap, Gaurav Shenoy, Snehal Kalyane, Dnyaneshwar Kalia, Kiran Tekade, Rakesh K. |
author_facet | Paul, Debleena Sanap, Gaurav Shenoy, Snehal Kalyane, Dnyaneshwar Kalia, Kiran Tekade, Rakesh K. |
author_sort | Paul, Debleena |
collection | PubMed |
description | • Artificial Intelligence (AI) has revolutionized many aspects of the pharmaceuticals. • AI assistance to pharma industries helps to improve overall life cycle of product. • AI can be implemented in pharma ranging from drug discovery to product management. • Future challenges related to AI and their respective solutions have been expounded. Artificial Intelligence (AI) has recently started to gear-up its application in various sectors of the society with the pharmaceutical industry as a front-runner beneficiary. This review highlights the impactful use of AI in diverse areas of the pharmaceutical sectors viz., drug discovery and development, drug repurposing, improving pharmaceutical productivity, clinical trials, etc. to name a few, thus reducing the human workload as well as achieving targets in a short period. Crosstalk on the tools and techniques utilized in enforcing AI, ongoing challenges, and ways to overcome them, along with the future of AI in the pharmaceutical industry, is also discussed. |
format | Online Article Text |
id | pubmed-7577280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75772802020-10-22 Artificial intelligence in drug discovery and development Paul, Debleena Sanap, Gaurav Shenoy, Snehal Kalyane, Dnyaneshwar Kalia, Kiran Tekade, Rakesh K. Drug Discov Today Review • Artificial Intelligence (AI) has revolutionized many aspects of the pharmaceuticals. • AI assistance to pharma industries helps to improve overall life cycle of product. • AI can be implemented in pharma ranging from drug discovery to product management. • Future challenges related to AI and their respective solutions have been expounded. Artificial Intelligence (AI) has recently started to gear-up its application in various sectors of the society with the pharmaceutical industry as a front-runner beneficiary. This review highlights the impactful use of AI in diverse areas of the pharmaceutical sectors viz., drug discovery and development, drug repurposing, improving pharmaceutical productivity, clinical trials, etc. to name a few, thus reducing the human workload as well as achieving targets in a short period. Crosstalk on the tools and techniques utilized in enforcing AI, ongoing challenges, and ways to overcome them, along with the future of AI in the pharmaceutical industry, is also discussed. Elsevier Ltd. 2021-01 2020-10-21 /pmc/articles/PMC7577280/ /pubmed/33099022 http://dx.doi.org/10.1016/j.drudis.2020.10.010 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Paul, Debleena Sanap, Gaurav Shenoy, Snehal Kalyane, Dnyaneshwar Kalia, Kiran Tekade, Rakesh K. Artificial intelligence in drug discovery and development |
title | Artificial intelligence in drug discovery and development |
title_full | Artificial intelligence in drug discovery and development |
title_fullStr | Artificial intelligence in drug discovery and development |
title_full_unstemmed | Artificial intelligence in drug discovery and development |
title_short | Artificial intelligence in drug discovery and development |
title_sort | artificial intelligence in drug discovery and development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/ https://www.ncbi.nlm.nih.gov/pubmed/33099022 http://dx.doi.org/10.1016/j.drudis.2020.10.010 |
work_keys_str_mv | AT pauldebleena artificialintelligenceindrugdiscoveryanddevelopment AT sanapgaurav artificialintelligenceindrugdiscoveryanddevelopment AT shenoysnehal artificialintelligenceindrugdiscoveryanddevelopment AT kalyanednyaneshwar artificialintelligenceindrugdiscoveryanddevelopment AT kaliakiran artificialintelligenceindrugdiscoveryanddevelopment AT tekaderakeshk artificialintelligenceindrugdiscoveryanddevelopment |